Monday, April 10, 2017
Effectiveness of bronchial thermoplasty in patients with severe refractory asthma: clinical and histopathological correlations
Asthma is a disease in which the airways of the lung become very sensitive to certain triggers, leading to spasms, in turn causing shortness of breath, coughing and wheezing. The ultimate cause of asthma is unclear, but it has been shown in previous studies that there is remodeling of the airways in severe asthma. Airway smooth muscle (ASM) increases, along with fibrosis, infiltration of new blood vessels, and growth of cells that line the airways. Recently, a procedure called bronchial thermoplasty (BT) has been developed, in which an endoscope is inserted into the airways. This endoscope then delivers a temperature-controlled radio frequency to the airway wall. In this month’s issue of JACI, Pretolani and colleagues look at bronchial thermoplasty and its effect on various clinical and histopathological findings (J Allergy Clin Immunol 2017; 139(4): 1176-1185).
In order to do this, they recruited 15 patients with severe uncontrolled asthma that did not respond to medications. They looked at the symptoms through the Asthma Control Test (ACT) and the Asthma Quality of Life Questionnaire (AQLQ), as well as breathing patterns via spirometry and biopsy samples. Bronchial thermoplasty was then performed. At 3 and 12 months, the clinical and airway effects were examined.
What they found is that asthma control and quality of life increased considerably. Exacerbations requiring oral steroids, emergency room visits, and hospitalizations were also decreased by approximately 90%. Biopsy samples from 3 months showed a decrease in ASM size, as well as nerve fibers and neuroendocrine cells.
Based on these results, Pretolani and colleagues conclude that bronchial thermoplasty is an option for severe, uncontrolled, treatment refractory asthma. Bronchial thermoplasty seems to affect the structure of airways, especially muscle size and nerve connections. Targeting these structures, through thermoplasty or other means may be an effective way to help control these difficult-to-control cases.
Thursday, April 6, 2017
A prospective study on the natural history of patients with profound combined immunodeficiency (P-CID): an interim analysis
The immune system is complex, composed of numerous cells, proteins, and other components. Among them, the T-cells are essential in fighting off infectious agents and regulating the functions of the immune system. People with reduced or dysfunctional T-cells can have life-threatening complications, and may require interventions like hematopoietic stem cell transplant (HSCT), gene therapy, or enzyme replacement. If a T cell deficiency is severe (severe combined immunodeficiency, SCID), these treatment decisions are clear. However, in patients with moderate T cell deficiency (profound combined immunodeficiency, P-CID), prognosis is unclear and transplant decisions are difficult. These patients have so far received little attention. In this month’s issue of JACI, Speckmann and colleagues report the first 51 P-CID patients enrolled in a long-term prospective study (J Allergy Clin Immunol 2017; 139(4): 1302-1310). The patients suffer from heterogenous T cell deficiencies including: (1) ‘bona fide’ CID, where deficiencies are typically associated with profound T-cell deficiencie, (2) atypical severe combined immunodeficiency (SCID), in which T-cell dysfunction is due to less life-threatening mutations in SCID-associated genes, and (3) T cell deficiencies with genetically unidentified cause. They analyzed the clinical and molecular characteristics at study entry to determine disease severity. Ultimately, the aim is to identify parameters predicting when the risks of untreated disease outweigh the risks of performing HSCT.
They found that patients with P-CID have a high rate of morbidity and mortality as well as a lower quality of life. One-third of patients underwent HSCT within the first year of inclusion into the study, 5 patients died. The genetic diagnosis has limited value as a predictor of disease evolution and thus as a guidance for HSCT decisions, with the age of onset, quality of life, and severity of disease not significantly different between patients with atypical SCID, bona fide CVID, or genetically undefined disease. This was in line with the authors’ expectations, but what they didn’t expect was that basic measures of T-cell immunity also did not predict the prognosis and course of their disease.
Speckmann and colleagues continue to enroll patients and hope to eventually reach their target of 120. Parallel long-term follow-up of transplanted and of non-transplanted patients will better identify predictors for the natural progress of P-CID, and, in turn, give better guidance about how, and when, to treat with HSCT.
Thursday, March 23, 2017
Food allergy is the leading cause of anaphylaxis, a serious and life-threatening systemic allergic reaction, among American children today. Although it can be managed by avoidance and supportive management, there are few options for disease modification. Oral immunotherapy (OIT) whereby increasing doses of an allergen are given, has been a promising investigational treatment, but the high rates of adverse reactions and intolerance of symptoms lead to high drop-out rates. In this month’s issue of JACI, MacGinnitie et al look at the use of omalizumab, an anti-IgE medication used in asthma, in helping to facilitate OIT (J Allergy Clin Immunol 2017; 139(3): 873-881).
To do this, they randomized 37 participants to receive either omalizumab or a placebo for 19 weeks, in addition to oral immunotherapy. Neither the patients nor the researchers knew the assignment of the groups. 6 weeks after stopping the omalizumab, it was found that a majority (79%) of the omalizumab group was able to achieve the 2000-mg maintenance dose. Even 12 weeks after stopping the omalizumab, 76% were able to tolerate even higher doses of peanut protein (4000mg). Even though the reaction rates were not statistically different between the two groups, the omalizumab group was also exposed to higher doses of peanut proteins.
Despite the small number of participants, this is encouraging news for the use of omalizumab as an adjunct for peanut oral desensitization. The authors suggest that the benefits of omalizumab-enabled OIT may outweigh the downsides of its expense, repeat injections, and risk of hypersensitivity reactions.
Body fat mass distribution and interrupter resistance, fractional exhaled nitric oxide, and asthma at school-age
Obesity and asthma are two of the most common childhood chronic diseases, seen in 25% and 10% of children, respectively. There are increasing lines of evidence suggesting that they may be inter-dependent : fat may be the source of proinflammatory mediators and may change the mechanics of lung function.
However, not all fat is considered equal. The android distribution of fat along the abdomen, compared to gynoid distribution along the hips, is more closely associated with a variety of cardiometabolic diseases. Similarly, visceral fat, situated just above the guts in the belly, is considered a marker of inflammatory status, compared to more superficial subcutaneous fat deposits. In this month’s issue of JACI, den Dekker and colleagues discuss the effect of body fat mass distribution on asthma and airway function in children (J Allergy Clin Immunol 2017; 139(3): 810-816).
To do this, they looked at the medical histories and physical characteristics of 6178 children. They focused on body-mass index (BMI), total and abdominal fat measures using ultrasonography and dual energy x-ray absorptiometry (DEXA), respiratory resistance (Rint), fractional exhaled nitric oxide (FENO), wheezing, and asthma. They found that a higher BMI was associated with increased respiratory resistance and current wheezing. They also noted that more visceral fat was associated with a higher FENO, while a higher android (belly)/gynoid (hip) ratio was associated with a lower FENO.
Altogether, these results suggest that local fat deposition, especially visceral fat, is more closely related to asthma. Even though the reasons for this are unclear, the authors speculate that maybe the different metabolic profiles of visceral vs. subcutaneous fat and the mechanical effects may be responsible for these differences. Regardless, understanding the finer details of fat composition and distribution may help to explain part of the increased prevalence of childhood asthma.
Novel baseline predictors of adverse events during oral immunotherapy in children with peanut allergy
Food allergy is a huge problem affecting 3 to 8% of school-age children. So far, avoidance and supportive management have been the mainstays of therapy, but this is rapidly changing with studies showing the efficacy of oral immunotherapy (OIT), especially for peanut allergies. In peanut OIT, gradually increasing doses of peanut are given as part of the buildup, with steady doses given during maintenance. The hope is to desensitize the immune system so that reactions are not as severe. In this month’s issue of JACI, Virkud and colleagues discuss the safety of oral immunotherapy to peanut by examining 104 patients from 3 peanut OIT trials (J Allergy Clin Immunol 2017; 139(3): 882-888). They look at the past medical history, parental reports, daily symptom diaries, and relationship to dose escalations to determine the risks and predictors of adverse effects (AEs).
The rate of AEs was high, with 80% experiencing at least 1 episode, and over 90% of these occurring at home. 42% of AEs were systemic reactions, but fewer than 50% received epinephrine, indicating a need for better patient education. About half of these AEs were gastrointestinal, and half of the patients who dropped out did so due to these gastrointestinal AEs; this amounted to 10% of all enrolled patients.
Overall, allergic rhinitis and the wheal size on peanut skin prick testing (SPT) were significant predictors of AEs. Allergic rhinitis approximately doubled the likelihood of having an AE, and seemed to explain why there was a higher rate of AEs during the spring and the fall. Asthma was also predictive of AEs during maintenance, but not in the buildup phase. Gastrointestinal AEs, like abdominal pain, nausea, vomiting, difficulty swallowing, and diarrhea, were also associated with the peanut SPT wheal size.
While there remains a lot to be learned about oral immunotherapy, this study helps to determine who would be the best candidates for this promising means of treating food allergies. Virkud and colleagues conclude that until there are rigorous well-designed and controlled trials, avoidance should remain the current standard of care.
Treatment of infants identified as having severe combined immunodeficiency by means of newborn screening
Severe Combined Immunodeficiency (SCID) is a set of fatal immune disorders in which infants are born without proper functioning immune systems needed to fight off infections. Fortunately, in recent years, there has been a push in several states for newborn screening (NBS) for early identification and life-saving treatment of these children. In this month’s issue of JACI, Dorsey and colleagues describe the protocol that they use in California, which has successfully identified 32 SCID patients and 46 non-SCID patients with decreased levels of T-cells (J Allergy Clin Immunol 2017; 139(3): 733-742).
Newborn screening is performed by measuring TRECs (T-cell receptor excision circles) which are formed upon gene rearrangement of the T-cell receptor. Peripheral blood count with differential and flow cytometry is the first follow up testing to determine the number of lymphocytes. This is followed by functional lymphocyte testing. If SCID is suspected, then children are placed in protective isolation and aggressively treated with antibiotics if needed. A SCID social worker coordinates with family in order to manage workup and identify needs for support, including emotional support.
Because allogenic and autologous hematopoietic stem cell (HSC) transplant is life-saving, Dorsey and colleagues relay that they apply three principles: (1) use of a donor with the least likelihood of graft-versus-host disease (GVHD), (2) minimize the duration of waiting for the SCT, and (3) use the least amount of chemotherapy necessary. Adherence to these principles has led to good outcomes: among the 32 that underwent transplant, 29 (94%) are alive and well.
Among the non-SCID patients, the protocol is more reliant on the degree of immunodeficiency, but nevertheless, they are followed up very closely by immunologists in the coming years to identify the status of their immune dysfunction. There remains a lot of work to be done in order to find out the best way to identify and treat SCID, but nationwide screening promises to accelerate our reaching that goal.
Tuesday, February 28, 2017
Humoral and cellular responses to casein in patients with food protein–induced enterocolitis to cow's milk
Food protein-induced enterocolitis syndrome (FPIES) is a type of food allergy in which children who eat milk, soy, or other foods develop repetitive vomiting and sometimes diarrhea. This can lead to dehydration, and, in the longer run, failure to thrive. But unlike more typical food allergies, FPIES isn’t mediated by IgE antibodies. In fact, what causes FPIES is still a bit of a mystery. In this month’s issue of JACI, Caubet and colleagues discuss results of their study on the immune responses seen in FPIES due to cow milk (CM-FPIES) (J Allergy Clin Immunol 2017; 139(2): 572-583).
To do this, they looked that the levels of antibodies, cytokines (chemical messengers), cell counts, and tryptase levels in 38 patients with active and resolved CM-FPIES. Oral food challenges (OFCs) were performed, and the results from positive OFCs were compared to those from negative OFCs.
What they found is that neutrophils could be responsible cells, which were found to be higher in patients with positive oral food challenges. The high levels of IL-8, a chemoattractant for neutrophils, also supported their conclusion. Mast cells may also participate, since IL-9 that was also high is produced by mast cells, and baseline tryptase levels were elevated. But interestingly, tryptase levels didn’t increase with the positive oral food challenge, meaning that mast cells weren’t activated during a challenge. Regulatory cytokines, such as IL-10 are likely related to the development of oral tolerance in FPIES. Additionally, levels of antibodies specific to casein, a key component of milk, were low in children with CM-FPIES. There remain a lot of unanswered questions about FPIES, but this study helps to shine some light on this mysterious type of food allergy.